Improved insulin sensitivity and islet function after PPARdelta activation in diabetic db/db mice

Area of Science:

• Endocrinology
• Metabolic Diseases
• Molecular Biology

Background:

• Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors involved in metabolic regulation.
• PPARdelta is known to regulate lipid metabolism, but its role in glucose metabolism is less understood.
• Type 2 diabetes is characterized by insulin resistance and impaired glycemic control.

Purpose of the Study:

• To investigate the effects of long-term PPARdelta activation on glycemic control, islet function, and insulin sensitivity.
• To evaluate the therapeutic potential of PPARdelta agonists in a mouse model of type 2 diabetes.

Main Methods:

• Male db/db mice, a model for type 2 diabetes, were treated daily with a selective PPARdelta agonist (NNC 61-5920) for eight weeks.
• Evaluated fasting and non-fasting plasma glucose, hemoglobin A1c, and glucose tolerance (oral and intravenous).
• Assessed insulin sensitivity using glucose and insulin injections during diazoxide-induced insulin secretion inhibition and analyzed isolated islet function and topography.

Main Results:

• Long-term PPARdelta activation significantly reduced plasma glucose and hemoglobin A1c levels.
• Improved oral and intravenous glucose tolerance was observed in treated mice.
• Insulin sensitivity was enhanced, and isolated islets showed improved glucose responsiveness and cellular structure.

Conclusions:

• PPARdelta agonism effectively alleviates insulin resistance and improves islet function in diabetic db/db mice.
• Activation of PPARdelta leads to improved glycemic control and may represent a promising therapeutic strategy for type 2 diabetes.
• Further research into PPARdelta as a target for type 2 diabetes treatment is warranted.